Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AQ-101 |
Synonyms | |
Therapy Description |
AQ-101 interferes with the interaction between MDM2 and MDM4 and induces degradation of MDM2, resulting in activation of Tp53, and potentially leading to decreased proliferation and increased apoptosis of tumor cells (PMID: 29282301). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AQ-101 | AQ101|AQ 101 | MDM2 Inhibitor 23 | AQ-101 interferes with the interaction between MDM2 and MDM4 and induces degradation of MDM2, resulting in activation of Tp53, and potentially leading to decreased proliferation and increased apoptosis of tumor cells (PMID: 29282301). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 over exp TP53 wild-type | acute lymphoblastic leukemia | sensitive | AQ-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AQ-101 inhibited growth and induced apoptosis in acute lymphocytic leukemia (ALL) cell lines with wild-type TP53 and overexpression of MDM2 in culture, and inhibited development of leukemia in ALL cell line xenograft models (PMID: 29282301). | 29282301 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|